Risk of Throat Cancer from Fosamax, Actonel, Boniva Found in Study

Long-term users of the bone-strengthening drugs Fosamax, Actonel, Boniva and other oral bisphosphonates may face a doubled risk of throat cancer, according to the results of a new study. 

The study is published in the latest issue of the British Medical Journal (BMJ), and it appears to contradict a similar study published last month that found no link between oesophageal cancer and oral biphosphonates like Fosamax.

Researchers from Oxford University looked at the UK General Practice Research Database and found that those subjects who filled 10 or more prescriptions for oral biphosphonates had nearly twice the chance of contracting throat cancer than those who were not taking the drugs. Researchers said that risk did not change regardless of age, sex, smoking, alcohol use, weight or the use of a variety of other drugs.

Still have questions?

Call (877) 932-2628 and speak with one of our legal funding experts.

* Word-Use Disclaimer

Legal funding is not a loan. It is the non-recourse purchase of an equitable lien in plaintiffs’ legal claims. Words such as ‘loans,’ ‘lending,’ ‘borrow,’ etc., are used for marketing purposes only.
More info

TriMark Legal Funding LLC
1056 Green Acres Rd #102
Eugene, OR 97408